Author: Luna Jade is a beauty market analyst focused on the Korean injectable ingredient market in China, with 10 years of experience in aesthetic and biotech trends across Asia.
Market Overview: China’s Aesthetic Surge and Korea’s Strategic Entry
The Korean injectable ingredient market in China has become one of Asia’s most talked-about growth stories in 2025.
Over the past decade, Chinese consumers have shifted from traditional skincare to minimally invasive aesthetic procedures, and injectables—fillers, botulinum toxins, and regenerative boosters—have led the charge.
According to China Association of Plastics and Aesthetics (CAPA), more than 16 million injectable procedures were performed in 2024, a 28 % year-on-year rise. Among imported products, Korean brands accounted for nearly 60 % of total injectable ingredient imports.
China’s growing middle-class population, rapid urbanization, and a cultural emphasis on “natural beauty with refinement” have accelerated the rise of aesthetic medicine.
At the same time, regulatory modernization under the NMPA (National Medical Products Administration) has opened official channels for certified Korean OEMs and ODMs that comply with Class III medical device standards.
In short, Korea’s expertise meets China’s demand—a combination transforming Asia’s medical aesthetics landscape.
Why Korean Brands Lead the Injectable Ingredient Race
Indeed, Korea’s dominance in the Chinese injectable scene is no coincidence. In fact, three inter-connected factors clearly explain why Korean labs continue to outpace both Western and local Chinese competitors.
1. Scientific Depth and Biotech Patents
Significantly, Korea’s pharmaceutical-cosmetic ecosystem serves as a bridge between dermatology and biotechnology. Building on this foundation, companies such as Medytox, Daewoong Pharmaceutical, and Hugel have pioneered peptide-stabilized botulinum and hybrid dermal fillers that incorporate polyglutamic acid (PGA) and polynucleotide complexes (PDRN).
2.Regulatory Compatibility
Unlike European firms that often struggle with NMPA translation and clinical equivalency, Korean companies maintain dual MFDS + NMPA documentation pipelines.
This shortens approval time by roughly 40 %, a decisive advantage in a fast-moving market.
3.Cultural Aesthetic Alignment
Both Korean and Chinese consumers prefer subtle, harmonious facial outcomes rather than drastic alterations.
Korean injectables are developed under the “natural correction” philosophy, allowing easier integration into Chinese clinics’ service models.
Consequently, the Korean injectable ingredient market in China is valued at approximately USD 910 million in 2025, with annual growth projected at 13–14 %.
Product Landscape: Botox, Collagen, and Regenerative Materials
| Brand / Manufacturer | Ingredient Type | NMPA Approval Status | Market Position | Distinctive Feature |
| Medytox / Hugel – Botulax | Type A Botulinum Toxin | Class III Approved | Top imported BTX | Rapid onset, smooth diffusion |
| Daewoong – Nabota (Jeuveau) | Purified Type A | NMPA Certified & FDA Cleared | Premium segment | Dual global certification |
| Huons – Liztox | Type A | Under review (expected 2025 H2) | Value tier | Affordable multi-dose vials |
| LG Chem – Zemetro | Recombinant Toxin | Clinical Phase III | Pipeline 2026 | Extended duration formula |
<Source: NMPA, (摩熵)DB, SHOYO(轻氧)>
Table 2 – Collagen Injectable Products (Korean Origin, China 2025)
| Brand / Manufacturer | Collagen Source | Certification | Target Segment | Key Strength |
| Toxnfill / Dermagen | Atelocollagen (Bovine) | NMPA Approved 2024 | Anti-aging clinics | Excellent biocompatibility |
| Cowellmedi – Col Fill Pro | Porcine Collagen + PGA | Clinical Pilot | Dermatology mid-tier | Gradual absorption + elasticity |
| ExoBiocell – Regen Colla | Recombinant Human Collagen | Approval 2025 H2 | Premium market | Allergen-free composition |
| Bioface – Derma Coll Marine | Marine Collagen | Local Distribution | Entry clinics | Sustainable marine source |
<Source: NMPA,모샹(摩熵)DB,SHOYO(轻氧)>
As consumer preferences evolve, collagen injectables have become especially popular among women aged 25–45 seeking non-toxin rejuvenation. Consequently, Korean brands combine collagen with bio-polymers such as PGA or PCL, which helps extend product durability to about nine months—twice the longevity of earlier products.
Table 3 – Regenerative Injection Materials (Stem-Cell / PDRN / Exosome / PGA)
| Brand / Manufacturer | Core Ingredient | Function | Market Use | Key Differentiation |
| TINA PGA – Recovery Booster | Polyglutamic Acid + EGF | Barrier repair & hydration | Scalp & skin booster segment | Patented Korean biopolymer |
| Caregen – Rejuran Healer | PDRN (Polynucleotide) | Dermal regeneration | Tier-1 clinic staple | Pioneer of PDRN therapy |
| ExoCoBio – ExoSCRT Serum | Exosome Complex | Cellular communication repair | Luxury centers Beijing / Shanghai | Clinical-grade exosome tech |
| Prostemics – StemCell Meso | MSC Extract | Anti-inflammatory rejuvenation | New launch 2025 Q4 | Long-term cellular pipeline |
<Source: NMPA,모샹(摩熵)DB,SHOYO(轻氧)>
Regulatory Evolution and Korea’s Strategic Adaptation
China’s 2023 Medical Device Supervision Measures revolutionized import procedures.
Before, imported fillers faced 18-month review cycles; now, under the new fast-track system, dual-certified foreign manufacturers can achieve NMPA clearance within 8–10 months if safety and clinical equivalence are proven.
Korean companies quickly aligned by:
- Establishing local subsidiaries in Shanghai Free Trade Zone for documentation.
- Partnering with Chinese CROs for clinical data validation.
- Implementing product serialization codes to prevent counterfeit circulation.
The Korean injectable ingredient market in China benefits enormously from these reforms, as compliance transparency strengthens buyer trust.
Growth Drivers: Consumer Mindset and Technology Transfer
1. Rising Self-Investment Among Young Professionals
As a result, a new generation of Chinese professionals now views injectables as a form of wellness maintenance rather than vanity.
They prefer light-touch treatments—micro-fillers, skin boosters, and exosome toners—often advertised on social media as “lunch-break procedures.”
Korean brands, with minimalist yet result-driven marketing, resonate perfectly with this demographic.
2. Medical-Aesthetic Convergence
Hospitals and skin clinics collaborate with Korean experts for live training.
In addition, leading institutions such as Amorepacific R&D Center and Seoul National University Hospital have established ongoing exchange programs with major Chinese hospitals, particularly in Chengdu and Hangzhou.
These collaborations transfer injection protocols, safety standards, and post-treatment care systems, enhancing Korea’s industry reputation.
3. Technological Transfer and OEM Expansion
By 2025, over 42 Korean OEM/ODM facilities supply China with ready-to-fill formulations.
This model allows Chinese brands to label-produce under Korean supervision, ensuring “K-grade quality” at local price levels—an essential step toward long-term scalability
Challenges Facing Korean Exporters
Even as success continues, several hurdles remain:
- Regulatory Delays for Novel Ingredients – exosome-based materials often require new clinical categories, extending NMPA processing time.
- Local Competition – biotech hubs in Guangzhou and Suzhou produce cost-effective HA fillers, reducing entry-level margins.
- Price Pressure – as distributors demand lower MOQ pricing, Korean firms must differentiate via R&D, not discounts.
- Counterfeit Concerns – illegal cross-border e-commerce still undermines brand image.
Korean companies counter these threats with serialized QR authentication, bilingual education campaigns, and regional after-service centers.
Market Outlook: 2025–2026 Forecast and Strategic Insights
By 2026, analysts project the Korean injectable ingredient market in China will exceed USD 1.25 billion, growing faster than any other imported aesthetic segment.
Regenerative and exosome-based lines will account for 35 % of total injectable imports, overtaking hyaluronic acid fillers for the first time.
Furthermore, hybrid formulations—combining PDRN + PGA or HA + Collagen—will define next-generation injectables designed for skin quality improvement rather than volume filling.
From a policy perspective, China’s regional governments in Guangdong, Hainan, and Chongqing are granting tax incentives and joint-lab funding to attract foreign medical-aesthetic R&D.
Korean firms already participate in 12 pilot projects co-funded by KOTRA and local health commissions, emphasizing long-term localization.
Broader Impact: Beyond Exports to Co-Creation
The relationship between Korea and China in aesthetics is shifting from exporter–importer to co-innovator partnership.
Meanwhile, Chinese biotech start-ups are now licensing Korean peptide patents, and as a result, Korean firms are also leveraging Chinese distribution networks to expand more rapidly across Asia.
However, this synergy produces regionally optimized products—lightweight formulas for humid southern climates, intensive repair boosters for northern dry zones, and even scalp-care injectables for urban stress markets.
Ultimately, the evolution of the Korean injectable ingredient market in China highlights a shared vision: sustainable growth through transparency, technology, and trust.
Related Reports:
China Lip Care Market Trends 2025
Inside the China Haircare Market 2025
Italy Cosmetic Import Trends Report 2025
Method & Source Notes
Data referenced from:
- KOTRA Shanghai & Beijing Trade Offices (2024–2025 Reports)
- NMPA Public Device Registration Database
- Euromonitor Beauty & Aesthetics Outlook 2025
- Interviews with executives from Medytox, Caregen, TINA PGA, ExoCoBio
- China Customs Trade Atlas for import volume validation.
Market forecast calculations used CAGR modeling (2022–2026) based on declared import prices of injectables across HA, BTX, collagen, and regenerative categories.
All brand names appear for analytical purposes only and imply no commercial endorsement.
Disclaimer
This article is an independent editorial analysis prepared for informational purposes.
It does not constitute financial, medical, or investment advice. Readers are encouraged to consult certified dermatologists or financial analysts for professional guidance.
Note
Ads shown on this page are automatically served by Google AdSense and are not related to affiliate content.